爱博医疗
(688050)
| 流通市值：130.80亿 | | | 总市值：133.28亿 |
| 流通股本：1.90亿 | | | 总股本：1.93亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 357,183,134.15 | 1,410,022,458.11 | 1,075,267,105.77 | 685,720,985.2 |
| 营业收入 | 357,183,134.15 | 1,410,022,458.11 | 1,075,267,105.77 | 685,720,985.2 |
| 二、营业总成本 | 265,024,934.1 | 984,684,592.28 | 720,300,574.45 | 452,709,844.75 |
| 营业成本 | 126,439,158.08 | 476,177,732.87 | 348,313,455.26 | 207,882,784.85 |
| 税金及附加 | 4,818,462.43 | 14,152,979.67 | 10,802,805.02 | 6,276,102.13 |
| 销售费用 | 61,398,115.87 | 199,035,731.28 | 150,875,501.68 | 107,063,911.5 |
| 管理费用 | 40,200,048.29 | 170,858,989.99 | 120,728,250.53 | 77,179,644.12 |
| 研发费用 | 26,197,363.6 | 107,198,444.18 | 77,654,725.68 | 47,193,968.44 |
| 财务费用 | 5,971,785.83 | 17,260,714.29 | 11,925,836.28 | 7,113,433.71 |
| 其中:利息费用 | 6,863,633.13 | 20,725,660.02 | 14,966,113.46 | 8,802,342.42 |
| 其中:利息收入 | -671,125.28 | 4,166,884.44 | 3,157,058.08 | 1,935,840.21 |
| 加:公允价值变动收益 | 536,517.2 | 146,997.41 | 49,221.52 | -102,851.97 |
| 加:投资收益 | 835,972.89 | -834,033.86 | 572,803.29 | 213,626.78 |
| 资产处置收益 | -148,627.9 | 19,342 | -71,647.36 | -49,641.59 |
| 资产减值损失(新) | -782,234.67 | -5,627,139.46 | 1,084,439.23 | 730,361.75 |
| 信用减值损失(新) | -2,700,174.68 | -10,902,216.99 | -11,128,691.56 | -8,813,315.67 |
| 其他收益 | 11,100,733.8 | 24,859,738.04 | 17,584,240.26 | 12,212,405.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 101,000,386.69 | 433,000,552.97 | 363,056,896.7 | 237,201,725.21 |
| 加:营业外收入 | 85,765.05 | 210,874.93 | 107,846.69 | 374,245.66 |
| 减:营业外支出 | 17,223.53 | 2,111,313.65 | 1,338,294.85 | 1,022,301.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 101,068,928.21 | 431,100,114.25 | 361,826,448.54 | 236,553,669.15 |
| 减:所得税费用 | 11,255,547.45 | 44,016,565.52 | 57,779,933.46 | 37,378,901.04 |
| 六、净利润 | 89,813,380.76 | 387,083,548.73 | 304,046,515.08 | 199,174,768.11 |
| 持续经营净利润 | 89,813,380.76 | 387,083,548.73 | 304,046,515.08 | 199,174,768.11 |
| 归属于母公司股东的净利润 | 92,558,116.8 | 388,402,949.75 | 317,592,430.52 | 208,040,759.23 |
| 少数股东损益 | -2,744,736.04 | -1,319,401.02 | -13,545,915.44 | -8,865,991.12 |
| (一)基本每股收益 | 0.49 | 2.05 | 1.68 | 1.1 |
| (二)稀释每股收益 | 0.49 | 2.05 | 1.68 | 1.1 |
| 八、其他综合收益 | 1,192,028.51 | 5,556,982.52 | 849,676.96 | 835,628.65 |
| 归属于母公司股东的其他综合收益 | 1,192,028.51 | 5,556,982.52 | 849,676.96 | 835,628.65 |
| 九、综合收益总额 | 91,005,409.27 | 392,640,531.25 | 304,896,192.04 | 200,010,396.76 |
| 归属于母公司股东的综合收益总额 | 93,750,145.31 | 393,959,932.27 | 318,442,107.48 | 208,876,387.88 |
| 归属于少数股东的综合收益总额 | -2,744,736.04 | -1,319,401.02 | -13,545,915.44 | -8,865,991.12 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-30 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |